The 32-participant registrational expansion cohort was not powered for statistically significant functional comparisons. The reported functional analysis was post hoc, combined placebo participants from the registrational and multiple-ascending-dose cohorts, and reported nominal p values; the prespecified plan did not include formal hypothesis testing of functional endpoints. Optional late biopsies involved four participants, compared with three baseline samples. Cardiopulmonary findings were compared with natural history and reflected mixed dose exposures, not continuous 20 mg/kg treatment throughout follow-up. Observational associations involving residual dystrophin should not be treated as direct proof of benefit from therapeutically restored dystrophin.